scholarly journals Effect of early palliative care on quality of life in patients with non-small-cell lung cancer

2018 ◽  
Vol 25 (1) ◽  
pp. 54 ◽  
Author(s):  
H. Zhuang ◽  
Y. Ma ◽  
L. Wang ◽  
H. Zhang
Keyword(s):  
Quality Of Life ◽  
Palliative Care ◽  
Pulmonary Function ◽  
Rating Scale ◽  
Life Quality ◽  
Small Cell ◽  
Control Group ◽  
Small Cell Lung ◽  
Early Palliative Care

Background Patients with metastatic non-small-cell lung cancer (nsclc) experience great pain and stress. Our study aimed to explore the effect of early palliative care on quality of life in patients with nsclc.Methods A total of 150 patients were randomly divided into two groups: control group with conventional care and study group with early palliative care. The quality of life (qol) rating scale and self-rating scale of life quality (sslq) were used to analyze the patients’ quality of life. The Hospital Anxiety and Depression Scale-D/A (hads-d/a) and Patient Health Questionnaire 9 (phq-9) were used to analyze the patients’ mood. Pulmonary function indexes of peak expiratory flow (pef), functional residual capacity (frc), and trachea-esophageal fistula 25% (tef 25%) were analyzed using the lung function detector.Results The qol and sslq scales scores of patients receiving early palliative care were significantly higher than those in the control group (p < 0.05). Moreover, the questionnaire results of the hads-d/a and phq-9 were better in patients receiving palliative care than in the control group (p < 0.05 or p < 0.01). In addition, analytical results of pulmonary function showed that the levels of pef, frc, and tef 25% in patients assigned to early palliative care were remarkably higher than those in the control group (p < 0.01 or p < 0.001).Conclusions These data demonstrate that early palliative care improves life quality, mood, and pulmonary function of nsclc patients, indicating that early palliative care could be used as a clinically meaningful and feasible care model for patients with metastatic nsclc.

Evaluating the Time to Palliative Care Referrals in Patients With Small-Cell Lung Cancer: A Single-Centre Retrospective Review

2018 ◽  
Vol 35 (11) ◽  
pp. 1426-1432
Author(s):  
Geoffrey Alan Watson ◽  
Jean Saunders ◽  
Linda Coate
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Palliative Care ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tertiary Hospital ◽  
Small Cell ◽  
Small Cell Lung ◽  
Early Palliative Care

Introduction: Lung cancer is a leading cause of morbidity and mortality worldwide. Patients with lung cancer may experience a plethora of symptoms, which can be debilitating and affect their quality of life. Palliative care input to manage their physical and psychological well-being is a crucial component of their oncological care. The benefit of early palliative care input has been shown in patients with non-small cell lung cancer; however, data pertaining to patients with small-cell lung cancer are scarce. Nevertheless, early palliative care input is recommended by several national and international guidelines. Thus, we aimed to assess the time to palliative care referrals in patients diagnosed with small-cell lung cancer in an Irish tertiary hospital and to determine what impact this had on overall survival. Methods: We performed a retrospective, single-center audit of all patients diagnosed with extensive stage small-cell lung cancer over a 6-year period in an Irish tertiary hospital. Results: Overall, 91 patients were identified. Median age at diagnosis was 66 years (range: 38-83 years). The median Eastern Cooperative Oncology Group Performance Status at diagnosis was 1 (range: 0-3); 24 (26%) patients had multiple sites of distant metastasis at diagnosis; 45 (49.5%) patients were alive at 6 months, and 15 (16.5%) patients were alive at 12 months. One hundred percent of patients received palliative care input in our center over the course of their care. In the patients alive at 6 months after diagnosis, there was no survival advantage in those receiving palliative care within 1 month ( P = .002, odd ratio: 0.23, 95% confidence interval: 0.09-0.59). Conclusion: Palliative care treatment is a critical aspect in the oncological treatment of all patients diagnosed with advanced cancer, and this study highlights good compliance with existing national guidelines. Further research focusing on quality-of-life issues with the use of questionnaires to assess physical and psychological symptoms should be performed to further understand the impact of palliative care in these patients.

scholarly journals Impact of Respiratory Symptoms and Pulmonary Function on Quality of Life of Long-term Survivors of Non-Small Cell Lung Cancer

CHEST Journal ◽  
2004 ◽  
Vol 125 (2) ◽  
pp. 439-445 ◽  
Author(s):  
Linda Sarna ◽  
Lorraine Evangelista ◽  
Donald Tashkin ◽  
Geraldine Padilla ◽  
Carmack Holmes ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Pulmonary Function ◽  
Small Cell Lung Cancer ◽  
Respiratory Symptoms ◽  
Small Cell ◽  
Small Cell Lung ◽  
Long Term Survivors

Ifosfamide, Carboplatin, and Etoposide With Midcycle Vincristine Versus Standard Chemotherapy in Patients With Small-Cell Lung Cancer and Good Performance Status: Clinical and Quality-of-Life Results of the British Medical Research Council Multicenter Randomized LU21 Trial

2005 ◽  
Vol 23 (33) ◽  
pp. 8371-8379 ◽  
Author(s):  
Nicholas Thatcher ◽  
Wendi Qian ◽  
Peter I. Clark ◽  
Penelope Hopwood ◽  
Robert J. Sambrook ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Performance Status ◽  
Small Cell ◽  
Control Group ◽  
Small Cell Lung ◽  
Standard Chemotherapy

Purpose Ifosfamide, carboplatin, etoposide, and vincristine, alone and in combination, are highly active against small-cell lung cancer (SCLC). This trial was designed to investigate whether survival could be improved by a regimen of all four drugs (ICE-V) compared with standard chemotherapy in patients with SCLC and good performance status, and to assess the patients’ quality of life (QL). Patients and Methods Patients were randomly assigned to receive six cycles of either ICE-V at 4-week intervals without dose reduction or standard chemotherapy administered according to local practice. The recommended standard control regimens were cyclophosphamide, doxorubicin, and etoposide; and cisplatin and etoposide. Results A total of 402 patients were randomly assigned, and 350 (87%) patients have died. Overall survival was longer in the ICE-V group (hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P = .0049), median survival was 15.6 months in the ICE-V group and 11.6 months in the control group, and 2-year survival rates were 20% and 11%, respectively. There was no evidence that the relative survival benefit for ICE-V was less in extensive-stage than in limited-stage patients. An increased rate of septicemia was reported in the ICE-V group (15% v 7% in the control group), but this did not result in an increase in reported treatment-related deaths (four patients [2%] in both groups). The findings on QL were broadly similar in both groups, with some benefit in favor of ICE-V. Conclusion Compared with standard chemotherapy, the ICE-V regimen improves overall survival without QL penalties, despite an increased but manageable level of toxicity.

Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life

1999 ◽  
Vol 17 (10) ◽  
pp. 3188-3194 ◽  
Author(s):  
M. H. Cullen ◽  
L. J. Billingham ◽  
C. M. Woodroffe ◽  
A. D. Chetiyawardana ◽  
N. H. Gower ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Palliative Care ◽  
Small Cell Lung Cancer ◽  
Survival Time ◽  
Median Survival ◽  
Median Survival Time ◽  
Small Cell ◽  
Small Cell Lung

PURPOSE: Chemotherapy for non–small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease. PATIENTS AND METHODS: Ambulatory patients with NSCLC, aged 75 years or younger, with localized disease, were randomized in MIC1 to receive up to four cycles of chemotherapy (CT: mitomycin 6 mg/m2, ifosfamide 3 g/m2, and cisplatin 50 mg/m2) every 21 days, followed by radical radiotherapy (CT + RT) or radiotherapy (RT) alone. Extensive-stage patients were randomized in MIC2 to identical chemotherapy plus palliative care (CT + PC) or palliative care (PC) alone. Short-term change in quality of life (QOL) was assessed in a subgroup of patients. Data from the two trials were combined to allow multivariate and stratified survival analyses. RESULTS: Seven hundred ninety-seven eligible patients were randomized, 446 in MIC1 and 351 in MIC2. MIC CT improved survival in both trials (significantly in MIC2). The median survival time in MIC1 was 11.7 months (CT + RT) versus 9.7 months (RT alone) (P = .14); whereas in MIC2, median survival time was 6.7 months (CT + PC) compared with 4.8 months (PC alone) (P = .03). QOL, assessed in 134 patients from start of trial to week 6, showed improvement with chemotherapy and deterioration with standard treatment. In the combined analysis of 797 randomized patients, the positive effect of MIC on survival was significant overall (P = .01) and after adjusting for prognostic factors (P = .01). CONCLUSION: MIC chemotherapy prolongs survival in unresectable NSCLC without compromising QOL.

scholarly journals Evaluation of quality of life in patients with locally advanced non-small cell lung cancer treated with combined radiochemotherapy

2003 ◽  
Vol 11 (3) ◽  
pp. 196-196
Author(s):  
Suzana Isakovic-Vidovic ◽  
Nenad Borojevic ◽  
Ljiljana Radosevic-Jelic ◽  
Tatjana Pekmezovic
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Control Group ◽  
Study Group ◽  
Small Cell Lung ◽  
Combined Radiochemotherapy

Background: The aim was to investigate the application of radiopotentiation which was initiated by the fact that in patients with locally advanced non-small cell lung cancer there is a high risk of relapse due to failure in local control of the disease and the risk of systemic micrometastases. The other aim was the evaluation of quality of life. Methods: A study group consisted of 67 patients. Patients were first treated with TD30 Gy in 10 fractions during 2 weeks (5 fractions per week) with a potentiation by 20 mg/m 2 of carboplatinol intravenous bolus infusion just prior to each radiotherapy fraction. After a 2-week pause, additional radiation of 25 Gy in 10 fractions was applied during 2 weeks (5 fractions/week) with a potentiation by 20 mg/m 2 of carboplatinol. Total tumor dose (TTD) was 55 Gy (30+25 Gy) in 20 fractions, total duration of the therapy was 6 weeks, and total dose of carboplatinol was 600 mg. A control group consisted of 70 patients and they were treated with a radical radiotherapy with a conventional fractionation (60 Gy in 30 fractions, 2 Gy per day, 5 fractions per week). Quality of life was evaluated by Karnofsky performance scale (KI), at the beginning of the treatment, after the completion of the whole course of treatment, and during follow-up at regular check-ups. Results After the completion of the whole course of treatment most of patients had KI 80%. Analysis made during the last check-up showed statistically significant low KI. In both study and control groups KI was significantly higher at the beginning of the treatment than KI after the completion of the whole course of treatment (p=0.001). However, the analysis of KI at the time of the completion of the whole course of treatment showed significantly better KI in study group (p=0.036) than in control group. Conclusion: These results showed that the combined radiochemotherapy treatment is well tolerated.

scholarly journals Effects of progressive Orff vocal therapy on BODE index and quality of life in patients with low lung function after non-small cell lung cancer surgery

2020 ◽  
pp. 1-7
Author(s):  
Yijie Du ◽  
Mingyue Su ◽  
Hongli Xue ◽  
Mengyu Ma ◽  
Xilong Wu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Function ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lung Cancer Surgery ◽  
Small Cell ◽  
Control Group ◽  
Small Cell Lung ◽  
Bode Index

Objective: To explore the effect of Orff vocal therapy on BODE index and quality of life of patients with low lung function after non-small cell lung cancer surgery. Methods: From March 2014 to March 2019, 231 patients with NSCLC postoperative (their pulmonary functions FEV1 [Formula: see text] of the expected value) in the Huashan Hospital, Fudan University were selected and randomly divided into observation groups and control group. On the basis of conventional treatment of NSCLC, the control group used lung rehabilitation training, and the observation group used the Orff music therapy. They carry out vocal and breath training step by step, using a combination of online and offline methods, 1[Formula: see text]h per day online interactive training, 2[Formula: see text]h of offline group vocal therapy once a week, continuous intervention for 12 months. The patient’s BODE index and FACT-L scores were monthly follow-up. Results: Compared with the control group, the BODE index and FACT-L scores improved more significantly in the vocal therapy group ([Formula: see text]). Especially in the FEV1pred, family/society module and functional status module, the improvement was most significant, compared with the control group ([Formula: see text]). And the loss of follow-up rate in the vocal therapy group was lower than that in the lung rehabilitation group ([Formula: see text]). Conclusion: Orff vocal therapy can improve the BODE index and quality of life of patients with low lung function after non-small cell lung cancer surgery, and its compliance and intervention effects are better than ordinary lung rehabilitation training.

Quality of Life of Long-Term Survivors of Non–Small-Cell Lung Cancer

2002 ◽  
Vol 20 (13) ◽  
pp. 2920-2929 ◽  
Author(s):  
Linda Sarna ◽  
Geraldine Padilla ◽  
Carmack Holmes ◽  
Donald Tashkin ◽  
Mary Lynn Brecht ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Pulmonary Function ◽  
Small Cell ◽  
Living Alone ◽  
Small Cell Lung ◽  
Sf 36 ◽  
Long Term Survivors

PURPOSE: To describe the quality of life (QOL) among survivors of non–small-cell lung cancer (NSCLC).PATIENTS AND METHODS: One hundred forty-two 5-year minimum self-reported disease-free survivors of NSCLC completed QOL instruments (QOL-Survivor and Medical Outcomes Study 36-Item Short Form [SF-36]) and assessments of emotional distress (Center for Epidemiologic Studies Depression Scale [CES-D]), comorbid disease, and tobacco use. Pulmonary function was assessed with a hand-held spirometer. Multivariate regression methods were used on total QOL-Survivor scores and physical (PC) and mental (MC) component scores of the SF-36.RESULTS: The majority (71%) of survivors described themselves as hopeful, and 50% viewed the cancer experience as contributing to positive life changes (QOL-Survivor). Comorbidity was common (60% ≥ one condition); 22% had distressed mood (CES-D ≥ 16). Most were former smokers (76%); 13% continued to smoke. Half had moderate/severe pulmonary distress (forced expired volume in 1 second [FEV1] < 70% of predicted). Regression models including the set of variables (age, sex, living alone, education, smoking status, pulmonary function category, distressed mood, time since diagnosis, and comorbidity) accounted for 37%, 48%, and 29% in the QOL-total, MC, and PC scores, respectively. Primary predictors of lower QOL scores were white ethnicity and distressed mood (CES-D ≥ 16) (34% of the variance explained). The primary predictor of lower MC scores was distressed mood (R2= 0.45). Lower PC scores were associated with older age, living alone, FEV1less than 70% of predicted, distressed mood, time since diagnosis, and more comorbid diseases (R2= 0.28).CONCLUSION: These findings provide the first description of the QOL of long-term survivors of lung cancer. Risk factors for poorer QOL are strongly linked to distressed mood, which is a potential target for intervention.

Sign in / Sign up

Export Citation Format

Share Document